Please wait while the formulary information is being retrieved.
SANDOSTATIN (OCTREOTIDE ACETATE)
- Acromegaly
- Carcinoid syndrome
- Diarrhea associated with VIp-secreting tumor
100 mcg/mL injection solution
- Inject 1 milliliter (100 mcg) by subcutaneous route 3 times per day
50 mcg/mL injection solution
- Inject 1 milliliter (50 mcg) by subcutaneous route 3 times per day
500 mcg/mL injection solution
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 3 times per day
1,000 mcg/mL injection solution
- Inject 0.1 milliliter (100 mcg) by subcutaneous route 3 times per day
100 mcg/mL injection solution
- Inject 1 milliliter (100 mcg) by subcutaneous route 3 times per day
200 mcg/mL injection solution
- Inject 1 milliliter (200 mcg) by subcutaneous route 3 times per day
50 mcg/mL injection solution
- Inject 1 milliliter (50 mcg) by subcutaneous route 3 times per day
500 mcg/mL injection solution
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 3 times per day
Acromegaly
- Inject 1 milliliter (50 mcg) by subcutaneous route 3 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 2 milliliters (100 mcg) by subcutaneous route 3 times per day
- Inject 2 milliliters (200 mcg) by subcutaneous route 3 times per day
- Inject 0.4 milliliter (200 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (500 mcg) by subcutaneous route 3 times per day
Carcinoid syndrome
- Inject 1 milliliter (50 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (50 mcg) by subcutaneous route 4 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 2 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 4 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 2 milliliters (100 mcg) by subcutaneous route 3 times per day
- Inject 2 milliliters (100 mcg) by subcutaneous route 2 times per day
- Inject 2 milliliters (100 mcg) by subcutaneous route 4 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 2 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 4 times per day
- Inject 0.4 milliliter (200 mcg) by subcutaneous route 2 times per day
- Inject 2 milliliters (200 mcg) by subcutaneous route 2 times per day
- Inject 2 milliliters (200 mcg) by subcutaneous route 3 times per day
- Inject 0.4 milliliter (200 mcg) by subcutaneous route 3 times per day
Diarrhea associated with VIp-secreting tumor
- Inject 1 milliliter (50 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (50 mcg) by subcutaneous route 4 times per day
- Inject 0.5 milliliter (50 mcg) by subcutaneous route 4 times per day
- Inject 0.1 milliliter (50 mcg) by subcutaneous route 4 times per day
- Inject 0.67 milliliter (67 mcg) by subcutaneous route 3 times per day
- Inject 0.14 milliliter (70 mcg) by subcutaneous route 3 times per day
- Inject 0.75 milliliter (75 mcg) by subcutaneous route 4 times per day
- Inject 0.15 milliliter (75 mcg) by subcutaneous route 4 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 2 times per day
- Inject 0.2 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 3 times per day
- Inject 1 milliliter (100 mcg) by subcutaneous route 2 times per day
- Inject 1.5 milliliters (150 mcg) by subcutaneous route 2 times per day
- Inject 0.3 milliliter (150 mcg) by subcutaneous route 2 times per day
- Inject 0.4 milliliter (200 mcg) by subcutaneous route 2 times per day
- None
Contraindicated
- None
Severe
Moderate
- cyclosporine
- cyclosporine modified
- Gengraf
- Neoral
- Sandimmune
- None
Contraindicated
- Biliary calculus
- Bradycardia
- Cardiac arrhythmia
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Gallbladder disease
- Hepatic cirrhosis
- Untreated hypothyroidism
Severe
Moderate
- Diabetes mellitus
- Hypoglycemic disorder
- Vitamin b12 deficiency
SANDOSTATIN (OCTREOTIDE ACETATE)
- Acromegaly
- Carcinoid syndrome
- Diarrhea associated with VIp-secreting tumor
- Bradycardia
- Cardiac arrhythmia
- Acute abdominal pain
- Back pain
- Constipation
- Diarrhea
- Disorder of the digestive system
- Fatigue
- Flatulence
- Injection site sequelae
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Biliary calculus
- Hypothyroidism
- Steatorrhea
- Depression
- Discolored feces
- Dizziness
- Dyspepsia
- Flushing
- General weakness
- Headache disorder
- Pruritus of skin
- Tenesmus
- Visual changes
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Acute pancreatitis
- Anaphylaxis
- Anemia
- Aphasia
- Appendicitis
- Atrial fibrillation
- Cellulitis
- Cholestasis
- Diabetes insipidus
- Diabetes mellitus
- Disease of liver
- Gastrointestinal hemorrhage
- Gastrointestinal obstruction
- Hearing loss
- Hemiparesis
- Hepatitis
- Hyperbilirubinemia
- Hyperglycemia
- Hypoglycemic disorder
- Intracranial bleeding
- Kidney disease with reduction in GFR
- Pancytopenia
- Paranoid disorder
- Pituitary apoplexy
- Pulmonary hypertension
- Renal failure
- Seizure disorder
- Suicidal
- Thrombocytopenic disorder
- Thrombosis of retinal vein
- Thrombotic disorder
- Visual field defect
Less Severe
- Abdominal distension
- Alopecia
- Arthralgias
- Arthritis
- Bell's palsy
- Edema
- Fever
- Flu-like symptoms
- Galactorrhea not associated with childbirth
- Gynecomastia
- Hematuria
- Libido changes
- Migraine
- Orthostatic hypotension
- Paresthesia
- Petechiae
- Raynaud's phenomenon
- Scotomata
- Urticaria
Contraindicated
None
Severe Precaution
Octreotide
Safety and efficacy not established. Risk of severe adverse effects of hypoxia, necrotizing enterocolitis, death, especially age < 2 years.
Increased incidence of new cholelithiasis compared to adults.
- 1 Day – 6 Years
- Safety and efficacy not established. Risk of severe adverse effects of hypoxia, necrotizing enterocolitis, death, especially age < 2 years.
- Increased incidence of new cholelithiasis compared to adults.
- 6 Years – 18 Years
- Safety and efficacy not established. Risk of severe adverse effects of hypoxia, necrotizing enterocolitis, death, especially age < 2 years.
- Increased incidence of new cholelithiasis compared to adults.
Management or Monitoring Precaution
None
Octreotide
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data suggest no developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Octreotide
Insufficient data available, absorption unlikely.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available, absorption unlikely. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Acromegaly | |
| E22.0 | Acromegaly and pituitary gigantism |
| Carcinoid syndrome | |
| E34.0 | Carcinoid syndrome |
| Diarrhea associated with VIp-secreting tumor | |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| R19.7 | Diarrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| C25.4 | Malignant neoplasm of endocrine pancreas |
| E22.0 | Acromegaly and pituitary gigantism |
| E34.0 | Carcinoid syndrome |
| R19.7 | Diarrhea, unspecified |
Formulary Reference Tool